{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:54:47Z","timestamp":1792119287046,"version":"4.4.0"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,10,7]],"date-time":"2011-10-07T00:00:00Z","timestamp":1317945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Alcoholism Clin &amp;amp; Exp Res"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:p><jats:bold>Background:\u2002<\/jats:bold> Pharmacotherapy studies in alcohol dependence (AD) are generally of short duration and do not include post\u2010treatment follow\u2010up. We examined the durability of treatment effects in a placebo\u2010controlled trial of sertraline for AD.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> As previously reported, patients received 12\u2003weeks of treatment with sertraline (<jats:italic>n<\/jats:italic>\u2003=\u200363) or placebo (<jats:italic>n<\/jats:italic>\u2003=\u200371), followed by assessments at 3 and 6\u2003months post\u2010treatment (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#b11\">Kranzler et\u00a0al., 2011<\/jats:ext-link>, J Clin Psychopharmacol 31:22\u201330). We examined the main and interaction effects with time of 3 between\u2010subject factors (medication group, age of onset of AD [late\u2010onset alcoholics, LOAs, vs. early\u2010onset alcoholics, EOAs], and the tri\u2010allelic 5\u2010HTTLPR genotype) on drinking days (DDs) and heavy drinking days (HDDs).<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> The medication group effect, which was significant during treatment, remained significant during the 3\u2010month follow\u2010up period for L\u2019\/L\u2019 LOAs, with the sertraline group having fewer DDs than the placebo group (<jats:italic>p\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.027). However, the medication group effect seen in L\u2019\/L\u2019 EOAs during treatment was no longer significant (<jats:italic>p\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.48). There were no significant effects in S\u2019 carriers at the 3\u2010month follow\u2010up visit, or in either genotype group at the 6\u2010month follow\u2010up.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> The beneficial effects of sertraline observed in LOAs during treatment persisted during the 3\u2010month post\u2010treatment period. Additional studies are needed to validate these pharmacogenetic findings, which together with the effects seen during active treatment support the use of sertraline only in LOAs.<\/jats:p>","DOI":"10.1111\/j.1530-0277.2011.01659.x","type":"journal-article","created":{"date-parts":[[2011,10,7]],"date-time":"2011-10-07T21:55:17Z","timestamp":1318024517000},"page":"739-744","source":"Crossref","is-referenced-by-count":24,"title":["Post\u2010Treatment Outcomes in a Double\u2010Blind, Randomized Trial of Sertraline for Alcohol Dependence"],"prefix":"10.1111","volume":"36","author":[{"given":"Henry R.","family":"Kranzler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Armeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Tennen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,7]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"American Psychiatric Association(1994)Diagnostic and Statistical Manual of Mental Disorders.4th edn.American Psychiatric Association Washington DC."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820080007002"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2003.11.012"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2882604"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ALC.0000130974.50563.04"},{"key":"e_1_2_7_7_1","unstructured":"FirstM SpitzerR GibbonM(2001)Structured Clinical Interview for DSM\u2010IC\u2010TR Axis I Disorders Research Version. Patient Edition with Psychotic Screen (SCID\u2010I\/P W\/PSYSCREEN).Biometric Research New York State Psychiatric Institute New York."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ALC.0000150008.68473.62"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/503850"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ALC.0000130806.12066.9C"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31820465fa"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1996.tb01696.x"},{"key":"e_1_2_7_13_1","first-page":"6311","volume-title":"Principles of Addiction Medicine","author":"Kranzler HR","year":"2009"},{"key":"e_1_2_7_14_1","article-title":"Comparison of alcoholism subtypes as moderators of the response to sertraline treatment","author":"Kranzler HR","journal-title":"Alcohol Clin Exp Res"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cne.902740211"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286150804200402"},{"key":"e_1_2_7_17_1","unstructured":"MillerW ToniganJ LongabaughR(1995)The Drinker Inventory of Consequences (DrInC): an instrument for assessing adverse consequences of alcohol abuse inNIAAA Project MATCH Monograph Series Volume 4(DHHS Publication No. 95\u20103911).National Institute on Alcohol Abuse and Alcoholism Rockville."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4000698"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2000.tb04648.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01808.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","unstructured":"SingerJD WillettJB(2003)Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence.Oxford University Press New York.","DOI":"10.1093\/acprof:oso\/9780195152968.001.0001"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-0357-5_3"}],"container-title":["Alcoholism: Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1530-0277.2011.01659.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1530-0277.2011.01659.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T08:31:36Z","timestamp":1698741096000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1530-0277.2011.01659.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,7]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1530-0277.2011.01659.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1530-0277.2011.01659.x","archive":["Portico"],"relation":{},"ISSN":["0145-6008","1530-0277"],"issn-type":[{"value":"0145-6008","type":"print"},{"value":"1530-0277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,7]]}}}